S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.79 (-3.85%)
AAPL   111.29 (-4.55%)
MSFT   202.47 (-5.06%)
FB   268.01 (-5.39%)
GOOGL   1,510.86 (-5.51%)
AMZN   3,168.26 (-3.59%)
TSLA   406.95 (-4.17%)
NVDA   505.75 (-5.62%)
BABA   308.41 (-2.75%)
CGC   18.34 (-1.71%)
GE   7.41 (+4.37%)
MU   50.03 (-3.71%)
AMD   76.48 (-3.04%)
T   26.46 (-1.71%)
F   7.72 (-2.53%)
ACB   3.82 (-4.50%)
GILD   58.79 (-2.03%)
NFLX   486.44 (-0.51%)
NIO   27.53 (-3.20%)
BA   148.21 (-4.53%)
DIS   118.52 (-3.88%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.79 (-3.85%)
AAPL   111.29 (-4.55%)
MSFT   202.47 (-5.06%)
FB   268.01 (-5.39%)
GOOGL   1,510.86 (-5.51%)
AMZN   3,168.26 (-3.59%)
TSLA   406.95 (-4.17%)
NVDA   505.75 (-5.62%)
BABA   308.41 (-2.75%)
CGC   18.34 (-1.71%)
GE   7.41 (+4.37%)
MU   50.03 (-3.71%)
AMD   76.48 (-3.04%)
T   26.46 (-1.71%)
F   7.72 (-2.53%)
ACB   3.82 (-4.50%)
GILD   58.79 (-2.03%)
NFLX   486.44 (-0.51%)
NIO   27.53 (-3.20%)
BA   148.21 (-4.53%)
DIS   118.52 (-3.88%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.79 (-3.85%)
AAPL   111.29 (-4.55%)
MSFT   202.47 (-5.06%)
FB   268.01 (-5.39%)
GOOGL   1,510.86 (-5.51%)
AMZN   3,168.26 (-3.59%)
TSLA   406.95 (-4.17%)
NVDA   505.75 (-5.62%)
BABA   308.41 (-2.75%)
CGC   18.34 (-1.71%)
GE   7.41 (+4.37%)
MU   50.03 (-3.71%)
AMD   76.48 (-3.04%)
T   26.46 (-1.71%)
F   7.72 (-2.53%)
ACB   3.82 (-4.50%)
GILD   58.79 (-2.03%)
NFLX   486.44 (-0.51%)
NIO   27.53 (-3.20%)
BA   148.21 (-4.53%)
DIS   118.52 (-3.88%)
S&P 500   3,271.03 (-3.53%)
DOW   26,519.95 (-3.43%)
QQQ   271.79 (-3.85%)
AAPL   111.29 (-4.55%)
MSFT   202.47 (-5.06%)
FB   268.01 (-5.39%)
GOOGL   1,510.86 (-5.51%)
AMZN   3,168.26 (-3.59%)
TSLA   406.95 (-4.17%)
NVDA   505.75 (-5.62%)
BABA   308.41 (-2.75%)
CGC   18.34 (-1.71%)
GE   7.41 (+4.37%)
MU   50.03 (-3.71%)
AMD   76.48 (-3.04%)
T   26.46 (-1.71%)
F   7.72 (-2.53%)
ACB   3.82 (-4.50%)
GILD   58.79 (-2.03%)
NFLX   486.44 (-0.51%)
NIO   27.53 (-3.20%)
BA   148.21 (-4.53%)
DIS   118.52 (-3.88%)
Log in
OTCMKTS:MATN

Mateon Therapeutics Stock Forecast, Price & News

$0.18
-0.01 (-5.26 %)
(As of 10/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.18
Now: $0.18▼
$0.20
50-Day Range
$0.16
MA: $0.18▼
$0.20
52-Week Range
$0.08
Now: $0.18▼
$0.30
Volume26,212 shs
Average Volume191,091 shs
Market Capitalization$16.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Read More
Mateon Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.85 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
CIK908259
Webwww.mateon.com
Phone650-635-7000
Employees13

Debt

Debt-to-Equity RatioN/A
Current Ratio0.10
Quick Ratio0.10

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.20 per share
Price / Book0.90

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-6,640,000.00
Net MarginsN/A
Return on Equity-70.69%
Return on Assets-47.17%

Miscellaneous

Outstanding Shares89,602,000
Market Cap$16.13 million
Next Earnings Date11/16/2020 (Estimated)
OptionableNot Optionable
$0.18
-0.01 (-5.26 %)
(As of 10/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

How has Mateon Therapeutics' stock been impacted by COVID-19?

Mateon Therapeutics' stock was trading at $0.1210 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MATN shares have increased by 48.8% and is now trading at $0.18.
View which stocks have been most impacted by COVID-19.

When is Mateon Therapeutics' next earnings date?

Mateon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 16th 2020.
View our earnings forecast for Mateon Therapeutics.

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02).
View Mateon Therapeutics' earnings history.

Are investors shorting Mateon Therapeutics?

Mateon Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 8,500 shares, an increase of 1,600.0% from the September 30th total of 500 shares. Based on an average trading volume of 91,700 shares, the short-interest ratio is presently 0.1 days.
View Mateon Therapeutics' Short Interest.

Who are some of Mateon Therapeutics' key competitors?

Some companies that are related to Mateon Therapeutics include Elite Pharmaceuticals (ELTP), Entasis Therapeutics (ETTX), Clearside Biomedical (CLSD), AgeX Therapeutics (AGE), Aridis Pharmaceuticals (ARDS), Rockwell Medical (RMTI), Savara (SVRA), Mereo BioPharma Group (MREO), Appili Therapeutics (APLIF), Trevi Therapeutics (TRVI), Conatus Pharmaceuticals (CNAT), Oramed Pharmaceuticals (ORMP), Vistagen Therapeutics (VTGN), Edesa Biotech (EDSA) and Citius Pharmaceuticals (CTXR).
View all competitors.

What other stocks do shareholders of Mateon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Oramed Pharmaceuticals (ORMP), Synergy Pharmaceuticals (SGYP), SELLAS Life Sciences Group (SLS), VIVUS (VVUS), Idera Pharmaceuticals (IDRA), Ascent Solar Technologies (ASTI), BioDelivery Sciences International (BDSI) and Avid Bioservices (CDMO).

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the following people:
  • Dr. Vuong Trieu, Chairman & CEO (Age 57, Pay $166.53k)
  • Mr. Amit Shah, Chief Financial Officer (Age 53, Pay $66.5k)
  • Dr. Chulho Park Ph.D., Chief Technology Officer (Age 53, Pay $129.86k)
  • Dr. Larn Hwang, Chief Scientific Officer (Age 57)
  • Dr. Anthony E. Maida III, M.A., M.B.A., MA, MBA, Ph.D., Chief Clinical Officer of Translational Medicine & Director (Age 68)

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.18.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $16.13 million. Mateon Therapeutics employs 13 workers across the globe.

What is Mateon Therapeutics' official website?

The official website for Mateon Therapeutics is www.mateon.com.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 29397 AGOURA ROAD SUITE 107, AGUORA HILLS CA, 91301. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.